Pharmacogenomics of interferon beta and glatiramer acetate response: A review of the literature

Sunil Mahurkar, Vijayaprakash Suppiah, Catherine O'Doherty

Research output: Contribution to journalReview articlepeer-review

54 Citations (Scopus)


Multiple sclerosis (MS) is one of the most common inflammatory and degenerative autoimmune diseases of the central nervous system with considerable heterogeneity in all aspects, including response to therapy. A number of disease modifying drugs, including traditional first line agents such as, interferon-beta (IFN-β) and glatiramer acetate (GA) are available for disease management. However, a considerable number of patients fail to achieve adequate response at therapeutic doses of IFN-β or GA. This variability in response to treatment has prompted the search for prognostic markers in order to personalize and optimize therapy so as to treat MS more efficiently. This review will summarize the existing literature examining the pharmacogenomics of IFN-β and GA response in MS patients.

Original languageEnglish
Pages (from-to)178-186
Number of pages9
JournalAutoimmunity Reviews
Issue number2
Publication statusPublished or Issued - Feb 2014
Externally publishedYes


  • Genetics
  • Glatiramer acetate
  • Interferon beta
  • Multiple sclerosis
  • Pharmacogenomics
  • Response

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this